Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma

TLDR

The study used CHOP and HOP combination chemotherapy to treat patients with advanced non‑Hodgkin lymphoma. In 204 CHOP‑treated patients, 71% achieved complete remission (92% overall response), while 216 HOP patients had 61% complete remission (88% overall response); remission rates were higher in nodular versus diffuse lymphoma, rapid responses were common, and 1‑year disease‑free rates were 86% with COP and 80% with OAP.

Abstract

Combination chemotherapy with CHOP (cyclophosphamide, Adriamycin, vin-cristine, and prednisone) and HOP (Adriamycin, vincristine, and prednisone) was used as treatment for patients with pathologically staged, advanced non-Hodgkin's lymphoma. Among 204 evaluable patients treated on CHOP there were 71% complete remissions with 92% overall responses. Among the 216 evaluable patients on HOP there were 61% complete remissions and 88% responses. Complete remission rates among patients with histiocytic lymphoma were comparable to those of patients with lymphocytic disease. Patients with nodular lymphoma had higher rates of complete remission than their counterparts with diffuse lymphoma. This was noted with both CHOP (78% vs. 67%) and HOP (67% vs. 60%) induction therapy. Rapid responses were common, as more than 14% of complete remissions and 66% of overall responses were achieved with the first course of treatment. Patients in complete remission have been maintained with either cyclophosphamide, vincristine, and prednisone (COP) or arabinosyl cytosine, vincristine, and prednisone (OAP). After 1 year, 86% of patients on COP and 80% on OAP are projected to be free of disease.